# US 2026/0199350 A1 · Flavones, quinolinones, quinazolinones, and aurones, and uses in ck2-mediated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0199350 A1
- Document ID: US20260199350A1
- Status: Published application
- Kind: A1
- Application number: 19/131,341
- Filed: 2023-11-21
- Published: 2026-07-16
- Earliest claimed: 2022-11-22
- Assignees: The Salk Institute for Biological Studies
- Applicants: Salk Institute for Biological Studies
- Inventors: Ioana Ilinca Nitulescu; Fred H. Gage; James K. Tucker
- Web page: https://patentgrep.com/patent/US20260199350A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07D 491/052: the oxygen-containing ring being six-membered
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 215/233: only one oxygen atom which is attached in position 4
- C07D 239/91: with aryl or aralkyl radicals attached in position 2 or 3
- C07D 307/83: Oxygen atoms
- C07D 311/28: with aromatic rings attached in position 2 only
- C07D 311/30: not hydrogenated in the hetero ring, e.g. flavones
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 407/10: linked by a carbon chain containing aromatic rings
- C07D 471/04: Ortho-condensed systems
- C07D 491/04: Ortho-condensed systems
- C12N 9/99: Enzyme inactivation by chemical treatment
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Flavone, quinolinone, quinazolinone, and aurone derivatives are disclosed. The compounds have a structure according to formula I or formula II, or a pharmaceutically acceptable salt, hydrate, stereoisomer, or tautomer thereof. The compounds may inhibit CK2 enzyme activity. Some compounds selectively reduce or inhibit the CK2A2 enzyme subunit over the CK2A1 enzyme subunit.

## Claims

### Claim 1

A compound according to formula I or formula II, or a pharmaceutically acceptable salt, hydrate, stereoisomer, or tautomer thereof:
where each bond represented by “” is a single or double bond as needed to satisfy valence requirements;
Q1 is C—R1 or N;
Q2 is C—R2 or N;
Q3 is C—R3 or N;
Q4 is C—R4 or N;
Q5 is C—R5, N, or N—Rb;
Q6 is O, N, or N—Rb;
Z is O, S, or N—Rb;
R1 is X or H;
R2 is H or —ORa;
R3 is X or H;
R4 is H;
R5 is H;
R6 is
R7A and R7B independently are N or CH;
R8 is H or X;
R9 is hydroxy;
R10A and R10B independently are X, —ORa, C1-C5 aliphatic, substituted C1-C5 aliphatic, or cycloaliphatic;
R11 is O, —ORa, or N(Ra)2;
R12 is
furan-2-yl, or furan-3-yl;
R13A and R13B independently are N or CH;
R14 is H, X, or —ORa;
R15 is —ORa, H, cyano, tetrazolyl, or —CO2Ra;
R16 is H, X, —ORa, substituted aliphatic, cycloaliphatic, or alkynyl;
each Ra independently is H or C1-C5 aliphatic;
each Rb independently is H, C1-C5 aliphatic, or cycloaliphatic; and
X is halo,
wherein, when the compound has a structure according to formula I, at least one of Q1-Q4 is N, or Q5 is N or N—Rb, or Q6 is N or N—Rb, or R11 is other than O.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein:
R1 and R3 are X, and R2 is H or methoxy; or
R1 is X, R2 is methoxy or H, and R3 is H; or
R1 and R2 are H, and R3 is X.

### Claim 3 (depends on 1)

The compound according to claim 1, having a structure according to formula I, wherein:
Q5 is C—R5;
Q6 is O; and
R11 is O.

### Claim 4 (depends on 1)

The compound according to claim 1, having a structure according to formula I, wherein:
Q1 is C—R1 and R1 is X;
Q2 is N or CH;
Q3 is C—R3 and R3 is X; and
Q4 is C—R4.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein each X independently is Br or Cl.

### Claim 6 (depends on 1)

The compound according to claim 1, having a structure according to formula I, wherein R6 is
where:
(i) R9 is hydroxy; or
(ii) R10A and R10B independently are Br, Cl, F, I, —CF3, alkynyl, cyclopropyl, or —OCH3; or
(iii) both (i) and (ii).

### Claim 7 (depends on 1)

The compound according to claim 1, having a structure according to formula I-A or I-B:
where R1 is Br or Cl;
R3 is Br, Cl, or H;
Q2, R7A, and R7B independently are N or CH; and
R10A is Br or Cl.

### Claim 8 (depends on 1)

The compound according to claim 1, having a structure according to formula I-C, I-D, or I-E:
where R7A and R7B independently are N or CH;
R8 is H, Cl, or F; and
R10A is Br, Cl, F, I, —CF3, alkynyl, or cyclopropyl.

### Claim 9 (depends on 1)

The compound according to claim 1, having a structure according to formula I-F:
where Q1 is N or C—Br;
Rb is H, —CH3, or cyclopropyl;
R7A and R7B independently are N or CH;
R8 is H, Cl, or F; and
R10A is Br, Cl, F, I, —CF3, alkynyl, cyclopropyl, or —OCH3.

### Claim 10 (depends on 1)

The compound according to claim 1, having a structure according to formula I-G:
where Q2, R7A, and R7B independently are N or CH;
R1 is Cl or Br;
R3 is Cl, Br, or H;
Rb is H, —CH3, or cyclopropyl;
R8 is H, Cl, or F; and
R10A is Br, Cl, F, I, —CF3, alkynyl, cyclopropyl, or —OCH3.

### Claim 11 (depends on 1)

The compound according to claim 1, having a structure according to formula I-H:
where R2 is H or —OCH3;
Rb is H, —CH3, or cyclopropyl;
R7A and R7B independently are N or CH;
R8 is H, Cl, or F; and
R10A is Br, Cl, F, I, —CF3, alkynyl, cyclopropyl, or —OCH3.

### Claim 12 (depends on 1)

The compound according to claim 1, having a structure according to any one of formulas I-I to I-Q:
where R1 and R3 independently are Cl, Br, or H;
Rb is H, —CH3, or cyclopropyl;
R7B is CH or N;
R8 is H, Cl, or F; and
R10A is Br, Cl, F, I, —CF3, alkynyl, cyclopropyl, or —OCH3.

### Claim 13 (depends on 1)

The compound according to claim 1, having a structure according to formula II-A
where Z is O, S, N(H), N—CH3, or N-cyclopropyl;
R2 is H or —OCH3;
R3 is H or Br;
R13A and R13B independently are CH or N;
R14 is H, Cl, or F; and
R16 is Br, Cl, F, I, —CF3, alkynyl, cyclopropyl, or —OCH3.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The compound according to claim 1, wherein the compound is:

### Claim 16

A compound, wherein the compound is:

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable excipient.

### Claim 18 (depends on 1)

A method of reducing CK2 enzyme activity, comprising:
contacting a cell that expresses CK2 enzyme with an effective amount of one or more compounds according to claim 1, thereby reducing activity of the CK2 enzyme.

### Claim at position 19

19-22. (canceled)

### Claim 23 (depends on 18)

The method of claim 18, where contacting the cell with the one or more compounds comprises administering a therapeutically effective amount of the one or more compounds, or an amount of a pharmaceutical composition comprising the therapeutically effective amount of the one or more compounds, to a subject having a disease or condition characterized at least in part by dysregulated CK2 enzyme activity.

### Claim at position 21

24-28. (canceled)

### Claim 29 (depends on 23)

The method of claim 23, wherein the disease or condition is a neurodegenerative disease, cancer, cardiac hypertrophy, cystic fibrosis, bipolar disorder, depression, a viral infection, obesity, diabetes mellitus, atherosclerosis, epilepsy, or any combination thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the neurodegenerative disease is Alzheimer's disease, Huntington's disease, Parkinson's disease, multiple sclerosis, or amyotrophic lateral sclerosis.

### Claim at position 24

31-36. (canceled)
